(firstQuint)Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.

 Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled.

 For this study, cellular and humoral immune responses will be assessed.

 No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.

.

 Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T@highlight

The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge(R)).

